GHK-Cu

Dosing from the Literature

Published for skin: facial creams used for 12 weeks in studies of 41–71 women, twice a day in one; the reviews that report them give no concentration (Pickart et al., 2015; Pickart & Margolina, 2018). Not published: any human trial of injected GHK-Cu.

The figures below are what online guides describe; no human trial has tested an injected dose.

What It Is

GHK-Cu is the complex formed when the tripeptide (a chain of 3 amino acids) glycyl-L-histidyl-L-lysine (Gly-His-Lys, or "GHK") binds a single copper(II) ion. It was first isolated from human plasma by Loren Pickart in 1973 at the University of California, San Francisco. Pickart spent the subsequent five decades characterizing its biological activity; his reviews are cited throughout this page, but most GHK papers in PubMed come from other groups. His 2018 comprehensive review with Anna Margolina in the International Journal of Molecular Sciences (PMID 29986520) consolidates that half-century of work and is the most widely cited modern reference for the molecule.

GHK in its unbound form is a naturally occurring plasma peptide. Its plasma concentration declines with age — from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60, as Pickart reports (Pickart & Margolina, 2018) — a correlation used to frame GHK-Cu as a "youthful" signaling molecule whose decline tracks the age-related decline in connective-tissue repair capacity. Whether that correlation is causative or coincident remains an open question, but the framing is consistent across the literature.

What separates GHK-Cu mechanistically from most other peptides in the optimization space is the apparent scale of its gene-expression effect. Analyses using the Broad Institute's Connectivity Map (a database of genome-wide gene-expression responses to 1,309 compounds in five cancer cell lines) reported that GHK modulates the expression of roughly 4,000 human genes at a ≥50% expression-change threshold (Pickart et al., 2015; Pickart & Margolina, 2018). Whether that breadth is therapeutically relevant, noise-inflated, or context-dependent is another open question, but it does help explain the diversity of effects reported in the preclinical literature.

GHK-Cu is by far the most-studied copper peptide and is the active compound in a large number of commercial cosmeceutical products. Topical use is the dominant legitimate route. Subcutaneous and intramuscular use for systemic effects — skin rejuvenation, hair growth, tissue repair — is widely practiced in the optimization community but is off-label, and injectable GHK-Cu is not eligible for 503A compounding (its nomination was withdrawn; only non-injectable GHK-Cu is on Category 1).

Mechanism of Action

Its discoverer's reviews describe GHK-Cu as acting on many biological pathways at once (Pickart & Margolina 2018). The mechanisms below come from Pickart's and independent groups' work, mostly in cells and animals.

• Copper delivery via carrier-exchange — The tripeptide binds Cu²⁺ with high affinity, and in cultured cells GHK increased copper uptake (Pickart et al. 1980; PMID 7453802). Lysyl oxidase (LOX, collagen cross-linking), superoxide dismutase 1 (SOD1, antioxidant) and tyrosinase all require copper as a cofactor; no study has shown GHK-Cu supplying copper to any of them. In the rat wound chamber, copper chloride alone had no effect on collagen and GHK without copper did not stimulate it, which is why the authors read copper delivery to cells as part of the complex's action (Maquart et al. 1993; PMID 8227353).
• Collagen and matrix accumulation — GHK-Cu raised collagen synthesis in fibroblast cultures, starting between 10⁻¹² and 10⁻¹¹ M and peaking at 10⁻⁹ M, with no change in cell number (Maquart et al. 1988; PMID 3169264). In wire-mesh wound chambers implanted under the skin of rats, repeated GHK-Cu injections raised dry weight, DNA, total protein, collagen and glycosaminoglycan content with dose; elastin, measured as its desmosine and isodesmosine content, was present in small amounts and rose roughly in step with total protein (Maquart et al. 1993; PMID 8227353). No published study shows GHK-Cu supplying copper to lysyl oxidase.
• Gene-expression modulation (Connectivity Map) — Pickart's analyses of the Connectivity Map, whose profiles come from cancer cell lines, count about 4,000 human genes whose expression GHK changes by 50% or more, among them 47 DNA-repair genes raised and 5 lowered, and genes tied to tissue remodeling, antioxidant and anti-inflammatory responses; the group reads this as resetting gene activity toward health (Pickart et al. 2015; Pickart & Margolina 2018).
• Anti-inflammatory signaling — GHK and GHK-Cu lowered TNF-α-driven secretion of IL-6 (a pro-inflammatory cytokine) by normal human skin fibroblasts in culture (Gruchlik et al. 2012). In mice with induced lung injury, GHK-Cu lowered TNF and IL-6 production by blocking activation of NF-κB (a master inflammation switch) and p38 MAPK, as described in the Pickart group's review (Pickart & Margolina 2018).
• Anti-oxidant signaling — GHK-Cu raised antioxidant enzyme levels in rabbit wounds and superoxide dismutase activity in mice with lung injury, and GHK blocked copper-driven oxidation of LDL in a lab test, as described in the Pickart group's reviews (Pickart et al. 2015; Pickart & Margolina 2018). The group reports that copper bound to GHK loses its redox activity, which leaves less free copper to drive oxidative damage (Pickart et al. 2015).
• Hair follicles (analogue only) — The cited hair work is on the alanine analogue AHK-Cu, which lengthened human hair follicles ex vivo and raised dermal-papilla-cell proliferation in culture (Pyo et al. 2007, Arch Pharm Res); it tested neither GHK-Cu, nor mice, nor the length of the anagen phase.
• Skin in cosmetic studies — In 12-week placebo-controlled studies of 41 to 71 women with photoaged facial skin, GHK-Cu creams increased skin density and thickness and reduced laxity, fine lines and wrinkle depth; in one, biopsies showed more keratinocyte proliferation (Pickart et al. 2015). In cell culture and lab-grown skin models, copper-GHK raised keratinocyte proliferation (Kang et al. 2009).
• Matrix metalloproteinase (MMP) regulation — The Pickart group's review reports that GHK stimulates both the synthesis and the breakdown of collagen and glycosaminoglycans, and modulates both MMPs and their tissue inhibitors, TIMP-1 and TIMP-2 (Pickart et al. 2015).
• Angiogenesis (new blood vessel growth) — GHK-Cu increased blood-vessel formation in rabbit wounds (Pickart et al. 2015) and raised the blood-vessel growth factor VEGF in irradiated human skin fibroblasts in culture (Pollard et al. 2005). The Pickart group's review adds that GHK and related peptides released from the protein SPARC stimulate blood-vessel growth early in healing and inhibit it later (Pickart & Margolina 2018).
• Nervous-system / cognitive gene-expression analysis (Pickart 2017) — In-silico / in-vitro analysis suggests GHK modulates genes associated with nervous-system function and cognitive decline — hypothesis-generating rather than clinical.
• Cancer gene-expression modulation — In Connectivity Map data, GHK reversed the expression of 70% of 54 genes overactive in an aggressive metastatic colon cancer, and at 1–10 nM it slowed the growth of human neuroblastoma and lymphoma cells in culture, as described in the Pickart group's reviews (Pickart et al. 2015; Pickart & Margolina 2018). These are lab findings, not clinical results.

What the Research Shows

GHK-Cu has one of the longest research histories of any compound in the peptide space. The literature spans foundational copper-chelation biochemistry, wound-healing models, cosmetic skin trials, and exploratory gene-expression analyses.

• Discovery (Pickart & Thaler 1973) — Original isolation of the tripeptide activity from human plasma; its amino-acid sequence and its copper binding were established in later studies (Pickart et al. 2015).
• Copper-uptake mechanism (Pickart et al. 1980, Nature) — Demonstrated GHK facilitates cellular copper uptake.
• Collagen stimulation (Maquart et al. 1988, 1993) — Fibroblast collagen-synthesis stimulation in vitro and in vivo rat wound models.
• Wound healing in animals — Rat, rabbit, and pig studies demonstrating accelerated closure of incisional, excisional, diabetic, and chronic wounds with topical or injected GHK-Cu.
• Chronic leg ulcers (human; early 1990s, Pickart / ProCyte) — Clinical work demonstrating improved healing of venous stasis ulcers and pressure ulcers with topical GHK-Cu formulations.
• Cosmetic skin studies (as described in Pickart et al. 2015) — In 12-week placebo-controlled studies of 41 to 71 women with photoaged facial skin, GHK-Cu creams increased skin density and thickness and reduced fine lines and laxity. A separate thigh-skin study found more collagen production in 70% of women using GHK-Cu cream, against 50% with vitamin C cream and 40% with retinoic acid.
• Hair growth (Pyo 2007) — The alanine analogue AHK-Cu lengthened human hair follicles ex vivo and raised the proliferation of cultured dermal papilla cells. No animal or human hair-density result, and no anagen measurement, is in the cited work.
• Skin regeneration review (Pickart, Vasquez-Soltero & Margolina 2015, Biomed Res Int) — Summarized in-vivo and in-vitro evidence for skin regeneration across species.
• Emphysema gene-expression signal (Campbell 2012, PMID 22937864) — An independent group used the Connectivity Map to identify GHK as reversing a gene-expression signature of emphysema-related lung destruction, then found that GHK restored collagen remodeling by lung fibroblasts from people with COPD, in culture — a non-skin application of the gene-expression framework.
• CNS gene-expression (Pickart 2017, Brain Sci) — In-silico analysis of GHK effects on genes relevant to cognitive decline. Hypothesis-generating rather than clinical.
• Regenerative and Protective Actions (Pickart & Margolina 2018, PMID 29986520) — Comprehensive 50-year synthesis review. The most-cited modern GHK-Cu reference.
• Topical penetration data (Hostynek 2011, PMID 20721598) — Characterized penetration of the copper tripeptide across skin layers in vitro.
• Modern cosmeceutical validation — GHK-Cu is an active ingredient in many clinically tested cosmetic products. Independent placebo-controlled trials report modest but consistent cosmetic-grade improvements.

Human Data

Human evidence for GHK-Cu is concentrated in topical cosmetic and chronic-wound applications; systemic injectable human evidence is extrapolation.

• Venous leg ulcers (ProCyte, 1990s) — Topical copper-peptide formulations tested in chronic wound care with positive healing outcomes in controlled clinical settings.
• Photoaged skin cosmetic creams (as described in Pickart et al. 2015) — Three 12-week placebo-controlled studies in 41 to 71 women reported denser, thicker, firmer skin and fewer fine lines; collagen production was measured in a separate thigh-skin study, where it rose in 70% of women using GHK-Cu cream.
• Diabetic ulcers — Small clinical series with topical GHK-Cu reporting accelerated closure; underpowered for formal conclusions.
• Hair growth — Small clinical studies on topical / intradermal GHK-Cu reporting increased hair density and terminal-hair conversion; practice continues to explore.
• Post-procedural skin — Dermatology case series exploring GHK-Cu in post-laser, post-microneedling, and post-surgical skin recovery.
• Cosmetic market penetration — Hundreds of commercial GHK-Cu products have been sold since the 1990s, generating post-market exposure data with a clean safety record at topical doses.
• No systemic RCT — No randomized controlled trial of systemic SubQ or IM GHK-Cu for anti-aging, tissue-repair, or cognitive endpoints has been published in a peer-reviewed journal.

This is a compound whose topical human data is real and clinically positive, and whose systemic injectable data is still largely preclinical / mechanistic with meaningful safety extrapolation from topical use. Off-label SubQ use carries the usual gray-market considerations — compound purity, appropriate dose, sterile technique.

Reconstitution & Storage

Sellers and online guides list injectable GHK-Cu as a freeze-dried powder in 50 mg and 100 mg vials; one guide describes the powder as off-white to pale blue, depending on its copper content.

• Reconstitution — Online guides describe adding the bacteriostatic water down the inside wall of the vial and swirling rather than shaking, and the mixed solution as clear with a faint blue tint from the copper.
• Storage — Online guides list the unmixed powder frozen at −20°C for long-term storage and the mixed solution refrigerated at 2–8°C, protected from light.
• Topical formulations — In a formulation study described in the Pickart group's review, GHK stayed stable in water between pH 4.5 and 7.4 for at least two weeks at 60°C but was prone to breakdown under oxidative stress (Pickart et al., 2015).
• Injection sites — Online guides describe subcutaneous injection into the abdomen, outer thigh or upper arm, with sites rotated.
• Inspection — Online guides describe discarding a mixed solution that turns cloudy or shows particles.

→ Calculator — vial-to-syringe math

Side Effects & Risks

For topical use, its discoverer's group reports no safety problems in cosmetics or in human wound-healing studies (Pickart et al., 2015), and an independent lab describes copper peptides as well tolerated on skin (Gruchlik et al., 2012). Injected GHK-Cu on its own has no published human safety data.

• Topical irritation — Online guides relay user reports of mild redness, tingling, dryness or irritation where it is applied, more often at higher concentrations.
• Injection-site reactions — Online guides relay user reports of redness, warmth, mild swelling and occasional bruising where it is injected.
• Copper overload (theoretical) — GHK binds copper mainly one to one (Trapaidze et al., 2012), so each injection also delivers copper; what months of daily injections do to the body's copper has not been studied in people.
• Vitamin C and acids — Online guides describe keeping GHK-Cu out of the same application as low-pH vitamin C and other acids, citing pH and irritation.
• Pre-existing cancer (theoretical) — GHK was first described as stimulating the growth of liver-cancer cells (Pickart & Thaler, 1973), and GHK-Cu raised the blood-vessel growth factor VEGF in cultured human fibroblasts (Pollard et al., 2005). Other lab work points the other way: GHK slowed the growth of human neuroblastoma and lymphoma cells, and the Pickart group reports that GHK-Cu given with vitamin C strongly suppressed a sarcoma in mice (Pickart & Margolina, 2018). Online guides list active cancer as a reason not to use it.
• Wilson's disease / copper-overload conditions — Online guides list copper-handling disorders such as Wilson's disease as a reason not to use it, because of the copper each dose carries.
• Pregnancy / lactation — Online guides note that it has not been studied in pregnancy or breastfeeding.
• Purity concerns — Injectable GHK-Cu is sold as a research chemical, not as a regulated drug. One online guide describes the powder as off-white to pale blue, depending on its copper content and the maker's process.
• WADA status — Not specifically named on the Prohibited List as of 2026; no major performance-enhancing profile documented. The tissue-repair peptide class could plausibly be evaluated under S0 for tested athletes.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for GHK-Cu. One online guide lists a baseline blood count and metabolic panel before repeated injections, with copper and ceruloplasmin as optional. The topical studies tracked skin density and thickness, laxity and wrinkles (Pickart et al., 2015).

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Practical User Notes

Legal Status

Related Compounds

People researching GHK-Cu often also look at these:

Next Steps

References

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID: 4349963. (Original discovery publication.)
2. Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. PMID: 7453802.
3. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343-346. PMID: 3169264.
4. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. PMID: 8227353.
5. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520. doi:10.3390/ijms19071987. (Comprehensive modern review.)
6. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730.
7. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017;7(2):20. PMID: 28212278.
8. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxid Med Cell Longev. 2012;2012:324832. PMID: 22666519.
9. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PMID: 17703734.
10. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med. 2012;4(8):67. PMID: 22937864.
11. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. PMID: 20721598.
12. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PMID: 15655171.
13. Kang YA, Choi HR, Na JI, Huh CH, Kim MJ, Youn SW, Kim KH, Park KC. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-306. PMID: 19319546.
14. Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2012;69(6):1303-1306. PMID: 23285694.
15. Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 2012;18(11):685-690. doi:10.1002/psc.2455. (Copper-independent activity comparator.)
16. Trapaidze A, Hureau C, Bal W, Winterhalter M, Faller P. Thermodynamic study of Cu²⁺ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. PMID: 21898044.
17. Mazurowska L, Mojski M. Biological activities of selected peptides: skin penetration ability of copper complexes with peptides. J Cosmet Sci. 2008;59(1):59-69. PMID: 18350235.
18. Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts. Arch Int Pharmacodyn Ther. 1995;330(3):345-360. PMID: 8836453.
19. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025-2026.
20. WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org.
21. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
22. Stone W. The wellness world is eager for RFK Jr.’s promised move on peptides. NPR, March 31, 2026. npr.org/2026/03/31/nx-s1-5768206/peptides-rfk-fda-compounding-pharmacies. Read October 3, 2026. (The HHS secretary’s late-February podcast remarks, “about 14” peptides; reported, not a rule.)

Related Research

• AHK-CuCopper Tripeptide (Hair)
• Pal-AHKCosmetic Hair / Skin Tripeptide (Lipidated)
• BPC-157Tissue Repair & Cytoprotection
• BPC-157 FragmentTissue Repair (Derivative of BPC-157)
• Glow StackBPC-157 · GHK-Cu · TB-500 — skin & tissue repair protocol
• KLOW StackBPC-157 · GHK-Cu · KPV · TB-500 — gut healing protocol
• FDA TrackerGHK-Cu is one of 12 peptides under FDA Pharmacy Compounding Advisory Committee review for the 503A Bulks List.